Physician profile
Barbara A Scheetz
NPI 1467488858
$2,514.06
in general payments reported to CMS, 2019-2025
15 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $173 · 2021: $260 · 2022: $418 · 2023: $449 · 2024: $392 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $733.99 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Johnson & Johnson Vision Care, INC. | $598.16 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $209.95 | 2024-2025 | Xdemvy |
| Coopervision INC. | $199.06 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Oyster Point Pharma, INC. | $194.22 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $124.98 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.92 | 2019-2020 | |
| Shire North American Group INC | $82.25 | 2019 | |
| Bausch & Lomb Americas INC. | $67.05 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Abb Con-Cise Optical Group LLC | $45.35 | 2019 | |
| Maculogix, INC. | $43.74 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Topcon Healthcare, INC. | $37.33 | 2024 | |
| Novartis Pharmaceuticals Corporation | $30.08 | 2019-2022 | |
| Allergan, INC. | $25.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Scheetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.